Mineralys Therapeutics Will Present Hypertension Data
New clinical trial results for the drug lorundrostat are set to be unveiled at a national cardiology conference.
Updated on Oct. 1, 2026 in Heart Disease
Live Poll
Do you trust that new medical innovations are improving the management of chronic high blood pressure?
Mineralys Therapeutics will share findings from five research abstracts regarding the drug lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026. The event takes place in Arlington, Virginia, from October 7-11, 2026.
Why it matters
The company aims to address hypertension and associated outcomes in conditions like obstructive sleep apnea and chronic kidney disease. These results are significant given that dysregulated aldosterone levels drive hypertension in approximately 30% of patients.
Lorundrostat showed a 40-70% reduction in plasma aldosterone concentration during clinical testing. The drug features a 374-fold selectivity for aldosterone-synthase inhibition and an observed half-life of 10-12 hours.
The players
Mineralys Therapeutics
A clinical-stage biopharmaceutical company headquartered in Radnor, Pennsylvania, that develops medicines for hypertension and related conditions.
American Heart Association
A prominent non-profit organization in the United States that funds cardiovascular medical research and hosts scientific conferences for health professionals.
The details
Researchers will present data from the Phase 3 Launch-HTN trial, which utilized a double-blind, placebo-controlled design, and the Phase 2 Explore-OSA study. The drug candidate is being developed to treat hypertension by specifically targeting the aldosterone-synthase pathway.
Timeline
2019: Annual US economic burden of hypertension reached $219 billion.
2022: Hypertension contributed to over 685,000 deaths in the United States.
October 7-11, 2026: AHA Hypertension Scientific Sessions take place in Arlington, Virginia.
October 8, 2026: Oral presentation of Explore-OSA trial results occurs.
October 9, 2026: Poster presentations regarding Launch-HTN trial and other studies take place.
The Big Picture
This release follows the standard industry pattern of using the American Heart Association Hypertension Scientific Sessions as the primary platform for revealing late-stage clinical trial findings. The focus on aldosterone-synthase inhibition represents a targeted shift in the treatment of hypertension.
These trials provide information on new therapeutic options for patients who do not respond to conventional hypertension treatments. While these results are for an investigational drug, they highlight potential future paths for managing aldosterone-related high blood pressure.
The takeaway
Advancements in aldosterone-synthase inhibitors represent a significant evolution in managing treatment-resistant hypertension. Patients should continue to monitor blood pressure levels and consult with healthcare providers regarding current standard treatments.
Further reading
For more information on the latest research and standard of care, visit Heart Disease.
More information
To review corporate updates and trial information, visit the Mineralys Therapeutics corporate website.
Live Poll
Do you trust that new medical innovations are improving the management of chronic high blood pressure?
